AU2018282105A1 - Dosing of vibegron for treatment of overactive bladder - Google Patents

Dosing of vibegron for treatment of overactive bladder Download PDF

Info

Publication number
AU2018282105A1
AU2018282105A1 AU2018282105A AU2018282105A AU2018282105A1 AU 2018282105 A1 AU2018282105 A1 AU 2018282105A1 AU 2018282105 A AU2018282105 A AU 2018282105A AU 2018282105 A AU2018282105 A AU 2018282105A AU 2018282105 A1 AU2018282105 A1 AU 2018282105A1
Authority
AU
Australia
Prior art keywords
vibegron
dosage
per day
weeks
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018282105A
Other languages
English (en)
Inventor
Paul Mudd
Stephen C. PISCITELLI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Urovant Sciences GmbH
Original Assignee
Urovant Sciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urovant Sciences GmbH filed Critical Urovant Sciences GmbH
Publication of AU2018282105A1 publication Critical patent/AU2018282105A1/en
Priority to AU2024204108A priority Critical patent/AU2024204108A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2018282105A 2017-06-06 2018-06-06 Dosing of vibegron for treatment of overactive bladder Abandoned AU2018282105A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024204108A AU2024204108A1 (en) 2017-06-06 2024-06-17 Dosing of vibegron for treatment of overactive bladder

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762516013P 2017-06-06 2017-06-06
US62/516,013 2017-06-06
US201862635310P 2018-02-26 2018-02-26
US62/635,310 2018-02-26
US201862637949P 2018-03-02 2018-03-02
US62/637,949 2018-03-02
PCT/IB2018/054070 WO2018224990A1 (en) 2017-06-06 2018-06-06 Dosing of vibegron for treatment of overactive bladder

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024204108A Division AU2024204108A1 (en) 2017-06-06 2024-06-17 Dosing of vibegron for treatment of overactive bladder

Publications (1)

Publication Number Publication Date
AU2018282105A1 true AU2018282105A1 (en) 2019-12-12

Family

ID=62815098

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018282105A Abandoned AU2018282105A1 (en) 2017-06-06 2018-06-06 Dosing of vibegron for treatment of overactive bladder
AU2024204108A Abandoned AU2024204108A1 (en) 2017-06-06 2024-06-17 Dosing of vibegron for treatment of overactive bladder

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024204108A Abandoned AU2024204108A1 (en) 2017-06-06 2024-06-17 Dosing of vibegron for treatment of overactive bladder

Country Status (9)

Country Link
US (3) US20210077496A1 (enExample)
EP (1) EP3634488A1 (enExample)
JP (2) JP7670461B2 (enExample)
KR (2) KR20250095747A (enExample)
CN (1) CN110869053A (enExample)
AU (2) AU2018282105A1 (enExample)
CA (1) CA3064973A1 (enExample)
MX (1) MX2023000187A (enExample)
WO (1) WO2018224990A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250099259A (ko) 2017-06-06 2025-07-01 유로반트 사이언시즈 게엠베하 과민성 방광의 치료를 위한 비베그론의 용도
JP7291632B2 (ja) * 2017-12-21 2023-06-15 杏林製薬株式会社 夜間頻尿治療剤
TW202038963A (zh) * 2018-12-05 2020-11-01 瑞士商優洛凡特科學公司 維貝隆（ｖｉｂｅｇｒｏｎ）於治療患有良性前列腺增生之男性中膀胱過動症症狀之用途
TW202506129A (zh) * 2019-03-18 2025-02-16 瑞士商優洛凡特科學公司 維貝隆（ｖｉｂｅｇｒｏｎ）用於治療膀胱過動症之用途
AR124479A1 (es) * 2020-12-22 2023-03-29 Urovant Sciences Gmbh Métodos de monitoreo de la digoxina con el uso de vibegrón para el tratamiento de la vejiga hiperactiva
KR20250051257A (ko) 2023-10-10 2025-04-17 (주)케이아트휀스 지주파이프 롤포밍 장치

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
US20120202819A1 (en) * 2009-10-07 2012-08-09 Merck Sharp & Dohme Corporation Combination therapy using a beta 3 adrenergic receptor agonists and an antimuscarinic agent
ES2584427T3 (es) 2011-10-27 2016-09-27 Merck Sharp & Dohme Corp. Proceso para la preparación de agonistas beta 3 y productos intermedios
WO2013062881A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
JP6383403B2 (ja) 2013-03-15 2018-08-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． β−３作動薬および中間体の製造方法
WO2017210696A1 (en) * 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder

Also Published As

Publication number Publication date
JP2020523334A (ja) 2020-08-06
KR20250095747A (ko) 2025-06-26
US20210077496A1 (en) 2021-03-18
JP7670461B2 (ja) 2025-04-30
AU2024204108A1 (en) 2024-07-04
WO2018224990A1 (en) 2018-12-13
MX2023000187A (es) 2023-02-09
CA3064973A1 (en) 2018-12-13
CN110869053A (zh) 2020-03-06
US20260199355A1 (en) 2026-07-16
JP2023058635A (ja) 2023-04-25
US20230218624A1 (en) 2023-07-13
EP3634488A1 (en) 2020-04-15
KR20200012939A (ko) 2020-02-05

Similar Documents

Publication Publication Date Title
EP4272818A3 (en) Thrombolytic agent for the treatment of thromboembolism
ZA202202361B (en) Treatment of hidradenitis suppurativa using jak inhibitors
EP4338804A3 (en) Epinephrine spray formulations
WO2017042607A3 (en) Compositions comprising meloxicam-cyclodextrin inclusion complexes and methods of treating acute pain
EP4368169A3 (en) Use of sublingual dexmedetomidine for the treatment of agitation
ZA202000028B (en) Use of vibegron to treat overactive bladder
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
FR3034993B1 (fr) Conditionnement unitaire, compositions et schemas therapeutiques pour l'administration de stimulateurs des voies de pro-resolution sur des surfaces keratiniques
GEP20247585B (en) Furoindazole derivatives
EP4324454A3 (en) Cross-linking agents and associated methods
EP4520398A3 (en) Treatment of prostate cancer
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
WO2020061486A3 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
PH12021551975A1 (en) Use of vibegron to treat overactive bladder
EP4461362A3 (en) Nk1-antagonist combination and method for treating synucleinopathies
EA202193276A1 (ru) Способы лечения холангиокарциномы
WO2018062876A3 (ko) 통증이 경감되는 골관절염 치료용 키트
WO2019126695A3 (en) Methods and pharmaceutical compositions for treating candida auris in blood
EP4537846A3 (en) Anavex2-73 for the treatment of alzheimer s disease
WO2021136841A3 (fr) Composition pharmaceutique pour la prevention ou le traitement des douleurs post-operatoires
WO2019236747A3 (en) Cyclic peptide compounds and methods of use thereof
MX2020001217A (es) Metodos de tratamiento de sintomas de gastroparesia usando velusetrag.

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted